Diego A Laplagne

Title: Diego A. Laplagne: Innovator in Chimeric Protein Technology

Introduction

Diego A. Laplagne is a notable inventor based in Argentina, recognized for his contributions to the field of biochemistry and protein engineering. His work primarily focuses on the development of isolated chimeric proteins, which have significant implications in vaccine development and therapeutic applications.

Latest Patents

Diego A. Laplagne holds a patent for "Isolated Chimeric Proteins Of Modified Lumazine Synthase." This invention includes isolated chimeric proteins that consist of up to ten copies of peptides, polypeptides, or protein domains inserted in the amino termini of the Brucella spp. Lumazine synthase enzyme. The patent also covers isolated nucleotide sequences that code for these chimeric proteins, as well as vectors, plasmids, and transformed cells used for expressing the proteins. Additionally, it includes monoclonal and polyclonal antibodies induced by the chimeric proteins, hybridomas producing these antibodies, and various applications such as vaccines and pharmaceutical compounds that incorporate the chimeric proteins, nucleotide sequences, and antibodies.

Career Highlights

Diego A. Laplagne has made significant strides in his career, particularly through his work at Goldgene LLC. His innovative approach to protein engineering has positioned him as a key figure in the development of new biotechnological solutions. Despite having no patents to his name, his research and inventions have the potential to impact various fields, including immunology and diagnostics.

Collaborations

Diego collaborates with Fernando A. Goldbaum, a fellow researcher, to advance their work in the field of chimeric proteins and their applications. Their partnership exemplifies the importance of collaboration in scientific research, particularly in developing new technologies.

Conclusion

Diego A. Laplagne is an influential inventor whose work on chimeric proteins holds promise for advancements in medical science. His contributions to the field are noteworthy, and his ongoing research may lead to significant breakthroughs in vaccine development and therapeutic applications.